NORCROSS, Ga.--(BUSINESS WIRE)--Aug. 22, 2006--Auriga Laboratories, Inc. (OTCBB:ARGA), a specialty pharmaceutical company dedicated to applying advances in drug delivery to improve and extend the value of medicines for improved patient outcomes and the marketer of the Extendryl(R) family of products, announces the execution of a strategic agreement with Degussa to develop a proprietary formulation targeting serious chronic gastrointestinal diseases utilizing Degussa’s proprietary EUDRACOL(TM) technology.
